Financial Results for the Quarter and Year ended March 31, 2026
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Caplin Point Laboratories reported strong FY2026 results with consolidated total revenue of ₹2,303 Crores, up 13.2% YoY (from ₹2,034 Crores). Net Profit After Tax grew 20.1% to ₹650 Crores (from ₹541 Crores). Q4 standalone revenue was ₹191 Crores and standalone PAT was ₹110 Crores. US market revenue was ₹471 Crores, growing 28.7% YoY, making it the fastest-growing segment. The company declared an interim dividend of ₹4 per share (200%). Free cash reserves stood at ₹1,471 Crores with total liquid assets of ₹2,726 Crores. The statutory auditor Brahmayya & Co. issued an unmodified opinion on both standalone and consolidated financial statements, confirming no qualifications.
The company delivered robust double-digit growth in both revenue and profit, with US business accelerating at nearly 29%. Strong cash reserves and a clean audit opinion are positive signals for investors. The interim dividend provides immediate shareholder reward.